ACE2 and lung cancer: In order to examine the restriction of SARS-CoV-2 replication by human antiviral proteins, we first sought to confirm the sensitivity of replication-competent SARS-CoV-2 (SARS-CoV-2 strain England 2) to type I (α and β), type II (γ), and type III (λ) IFNs in human A549 lung cancer cells stably expressing ACE2.